YOLFTbeta
Altimmune Inc

Altimmune Inc

ALT · NASDAQ · Healthcare / Biotechnology

1.65USD+0.03 (+2.17%)

Price History

Full chart

Market Stats

Previous Close1.61
Open1.64
Day Range1.58 – 1.67
52-Week Range2.56 – 6.44
Volume3.50M
Market Cap591.33M
P/E (TTM)0.00
Forward P/E8.18
EPS-0.73
Dividend Yield0.00%
Beta0.18
50-Day Avg3.08
200-Day Avg3.54

About

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Jerome Benedict Durso
  • Employees57
  • Headquarters910 Clopper Road, Gaithersburg, MD, United States, 20878, USA
  • Websitehttps://altimmune.com

Leadership

  • Mr. Jerome Benedict DursoChairman, CEO & President · b. 1968
  • Dr. M. Scot Roberts Ph.D.Chief Scientific Officer · b. 1959
  • Dr. Christophe Arbet-Engels M.B.A., M.D., Ph.D.Chief Medical Officer · b. 1963
  • Mr. Gregory L. Weaver CPA, M.B.A.Chief Financial Officer · b. 1956
  • Mr. Andrew Shutterly M.S.Principal Financial & Accounting Officer and Corporate Controller · b. 1988
  • Mr. Bertrand Georges Ph.D.Chief Technology Officer
  • Mr. Luis Sanay C.F.A.Vice President of Investor Relations
  • Mr. Tony Blandin B.S.Vice President of Quality & Compliance Management
  • Ms. Robin E. Abrams J.D.Chief Legal Officer & Corporate Secretary · b. 1964
  • Mr. Raymond M. Jordt M.B.A., M.S.Chief Business Officer · b. 1973

Financials

Income Statement

Currency: USD2005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue586.07K1.85M14.64M32.91M27.55M20.99M24.27M25.18M17.91M10.19M10.64M5.23M41.50K10.33M5.80M8.19M4.41M-68.00K426.00K20.00K41.00K
Growth (%)-+215.27%+692.53%+124.75%-16.29%-23.80%+15.59%+3.75%-28.85%-43.11%+4.42%-50.85%-99.21%+24792.58%-43.85%+41.09%-46.12%-101.54%+726.47%-95.31%+105.00%
Cost of Revenue115.00K-----0004.27M5.06M7.22M18.41M18.46M17.07M33.51M73.84M500.00K477.00K238.00K112.00K
Gross Profit471.07K1.85M14.64M32.91M27.55M20.99M24.27M25.18M17.91M5.93M5.58M-1.99M-18.36M-8.13M5.80M-25.32M4.41M-68.00K426.00K20.00K41.00K
Gross Margin80.38%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%58.15%52.41%-38.07%-44249.39%-78.68%100.00%-309.40%100.00%100.00%100.00%100.00%100.00%
Operating Expense145.78K644.38K31.15M68.15M53.52M44.55M35.99M31.44M28.75M16.12M8.98M9.27M33.68M34.71M27.27M29.47M101.32M87.67M96.36M103.19M94.53M
Operating Income325.30K1.20M-16.50M-35.24M-25.97M-23.55M-11.73M-6.27M-10.84M-10.19M-3.40M-11.26M-52.05M-42.83M-21.46M-54.80M-96.91M-87.74M-95.93M-103.17M-94.49M
Operating Margin55.50%65.13%-112.70%-107.09%-94.28%-112.19%-48.32%-24.89%-60.51%-100.01%-31.98%-215.37%-125401.20%-414.61%-370.00%-669.50%-2197.60%129029.41%-22518.54%-515860.00%-230460.98%
EBITDA325.30K1.20M-15.80M-33.03M-28.57M-23.26M-3.28M-4.08M-11.10M-9.53M-3.18M-10.91M-51.76M-44.72M-20.19M-38.10M-96.53M-84.41M-87.94M-94.81M-87.03M
EBITDA Margin55.50%65.13%-107.88%-100.35%-103.70%-110.78%-13.52%-16.20%-61.99%-93.55%-29.91%-208.65%-124720.16%-432.88%-348.00%-465.54%-2188.98%124130.88%-20642.02%-474060.00%-212258.54%
Net Income277.30K1.02M-13.59M-36.42M-32.28M-34.85M-3.80M-4.92M-11.72M-9.96M-3.44M193.85M-46.43M-39.17M-20.52M-49.04M-97.09M-84.71M-88.45M-95.06M-88.09M
Net Income Margin47.31%55.01%-92.79%-110.65%-117.17%-166.00%-15.65%-19.54%-65.42%-97.70%-32.34%3706.44%-111860.32%-379.16%-353.71%-599.20%-2201.59%124577.94%-20762.21%-475295.00%-214860.98%
R&D--16.56M31.81M30.22M20.88M21.22M19.51M15.29M9.32M5.13M4.84M18.41M18.46M17.77M49.77M74.54M70.54M65.80M82.23M66.43M
R&D as % of Total Revenue--113.08%96.66%109.69%99.44%87.45%77.49%85.36%91.46%48.24%92.46%44349.39%178.68%306.23%608.11%1690.27%-103732.35%15445.77%411130.00%162029.27%
Interest Expense002.12M2.57M2.84M5.94M54.57K342.56K369.28K210.40K54.58K38.50K162.14K297.09K2.24K9.42K5.00K8.00K35.00K9.00K1.64M
Interest Expense % of Total Revenue0.00%0.00%14.50%7.82%10.30%28.28%0.22%1.36%2.06%2.06%0.51%0.74%390.67%2.88%0.04%0.12%0.11%-11.76%8.22%45.00%3990.24%

Balance Sheet

Currency: USD2005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets70.09M71.74M66.61M56.39M34.07M27.20M22.80M22.74M17.14M21.98M19.86M224.74M63.03M54.75M54.06M245.12M218.86M206.93M210.64M139.31M279.93M
Total Liabilities410.54K14.63M26.04M37.43M32.18M14.99M6.95M11.07M9.80M3.70M3.21M205.28M14.35M6.44M8.54M19.24M19.73M21.64M16.54M15.80M55.04M
Total Equity69.68M57.11M40.57M18.96M1.88M12.21M15.85M11.67M7.34M18.27M16.65M19.46M48.68M48.31M45.52M225.88M199.13M185.29M194.10M123.51M224.89M
Cash1.40M675.30K40.58M19.75M2.67M11.79M11.24M12.70M10.48M18.64M15.57M153.99M8.77M33.72M8.96M115.92M190.30M111.10M135.12M36.93M43.76M
Total Debt--20.67M18.31M17.43M--3.78M2.82M746.15K1.08M1.99M4.62M1.92M2.12M2.19M1.87M1.12M671.00K1.68M35.69M
Net Debt-1.40M-675.30K-19.91M-1.45M14.75M-11.79M-11.24M-8.92M-7.66M-17.90M-14.49M-153.01M-8.72M-33.15M-7.22M-114.09M-188.77M-109.97M-134.45M-35.24M-8.07M

Cash Flow

Currency: USD2005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow554.33K1.53M-13.64M-13.20M-28.15M-14.86M-7.81M-2.32M-7.17M-8.47M-3.22M201.51M-20.21M-9.39M-9.60M-34.44M-78.24M-62.59M-75.81M-79.85M-67.53M
Investing Cash Flow-68.64M-2.25M-12.94M-10.10M-7.99M2.76M1.69M67.40K-81.08K-84.27K-78.91K-66.88M13.73M-1.00M-28.29M-72.09M87.52M-73.40M13.73M-28.39M-132.47M
Financing Cash Flow69.48M-61.93M2.41M18.79M21.46M5.78M3.72M5.03M16.73M223.13K3.80M15.84M32.49M12.53M213.49M65.10M56.78M86.11M10.04M206.84M
Capital Expenditure00882.35K509.31K1.03M374.58K71.44K084.58K92.27K86.51K30.69K166.33K1.02M29.00K342.42K12.31M126.00K47.00K011.00K
Free Cash Flow554.33K1.53M-14.52M-13.71M-29.18M-15.24M-7.88M-2.32M-7.25M-8.57M-3.30M201.48M-20.38M-10.40M-9.63M-34.78M-90.55M-62.71M-75.86M-79.85M-67.55M
Dividends Paid------000000022.90K3.79B135.47M-----
FCF to OCF100.00%100.00%106.47%103.86%103.66%102.52%100.91%100.00%101.18%101.09%102.69%99.98%100.82%110.82%100.30%100.99%115.74%100.20%100.06%100.00%100.02%
Dividend Paid to FCF------0.00%0.00%0.00%0.00%0.00%0.00%0.00%-0.22%-39367.53%-389.52%-----

Earnings

Report DateDec 31, 2005Mar 31, 2006Jun 30, 2006Sep 30, 2006Dec 31, 2006Mar 31, 2007Nov 13, 2007May 14, 2008Aug 13, 2008Nov 13, 2008Mar 30, 2009May 15, 2009Aug 13, 2009Nov 12, 2009Mar 23, 2010May 11, 2010Aug 12, 2010Nov 11, 2010Mar 28, 2011May 11, 2011Aug 10, 2011Nov 9, 2011Mar 8, 2012May 8, 2012Aug 7, 2012Nov 6, 2012Mar 13, 2013May 8, 2013Aug 7, 2013Nov 7, 2013Mar 11, 2014May 8, 2014Aug 4, 2014Nov 6, 2014Mar 9, 2015May 7, 2015Aug 5, 2015Nov 6, 2015Mar 11, 2016May 9, 2016Aug 4, 2016Nov 4, 2016Mar 14, 2017May 3, 2017Aug 10, 2017Nov 9, 2017Mar 28, 2018May 15, 2018Aug 14, 2018Nov 13, 2018Mar 31, 2019Apr 1, 2019Aug 13, 2019Nov 13, 2019Mar 27, 2020May 13, 2020Aug 11, 2020Nov 9, 2020Feb 25, 2021May 17, 2021Aug 10, 2021Nov 9, 2021Mar 15, 2022May 12, 2022Aug 11, 2022Nov 10, 2022Feb 28, 2023May 11, 2023Aug 10, 2023Nov 7, 2023Mar 27, 2024May 9, 2024Aug 8, 2024Nov 12, 2024Mar 25, 2025May 13, 2025Aug 12, 2025Nov 6, 2025Mar 26, 2026May 13, 2026Aug 12, 2026Nov 5, 2026
EPS Estimate----------78.00-78.00-60.00-54.00-57.00-61.50-51.00-61.50-52.00-26.00-29.00-31.50-25.00-32.00-15.00-9.00-9.00-12.00-15.00-9.00-10.50-15.00-18.00-16.50-7.500.00-0.000.000.000.000.000.000.00---8.40-15.00-15.00-4.50-3.60-2.80-2.80-0.25-0.19-0.26-0.32-0.28-0.76-0.80-0.74-0.53-0.39-0.65-0.58-0.49-0.51-0.50-0.48-0.46-0.44-0.43-0.35-0.34-0.36-0.34-0.34-0.32-0.27-0.25-0.25-0.15-0.14
EPS Actual4.814.476.116.64-11895.617.48-20.56-68.15-296.82-60.00-51.00-69.00-72.00-150.00-60.00-84.00-66.00-42.00-138.00-12.00-15.00-0.213.00-18.00-6.00-1.33-6.00-12.00-6.00-24.00-24.00-12.00-3.00-24.000.000.02-0.04-0.02-0.010.020.121.671.14-0.68-0.26-10.20-17.40-8.73-5.63-2.29-2.34-0.27-0.26-0.19-0.25-0.26-0.94-0.54-0.17-0.38-0.60-0.81-0.57-0.44-0.42-0.48-0.43-0.40-0.32-0.39-0.33-0.34-0.35-0.32-0.33-0.26-0.27-0.21-0.27-0.18-0.12-
Surprise---------23.08%34.62%-15.00%-33.33%-163.16%2.44%-64.71%-7.32%19.23%-430.77%58.62%52.38%99.17%109.38%-20.00%33.33%85.25%50.00%20.00%33.33%-128.57%-60.00%33.33%81.82%-220.00%------------21.43%-16.00%41.80%-25.11%36.39%16.43%90.36%-4.00%0.00%3.85%18.75%-235.71%28.95%78.75%48.65%-13.21%-107.69%12.31%24.14%14.29%5.88%14.00%16.67%30.43%11.36%23.26%2.86%-2.94%11.11%1.52%23.53%15.63%22.22%-8.39%28.00%20.00%-
Timing-------------------------------------After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap591.33M
Enterprise Value330.25M
Trailing P/E0.00
Forward P/E8.18
PEG Ratio32.62
Price / Sales19075.28
Price / Book1.31
EPS-0.73
Book Value2.44
Revenue (TTM)31.00K
Gross Profit (TTM)-66.69M
EBITDA-98.63M
Profit Margin0.00%
Operating Margin-318493.55%
Return on Equity-28.88%
Return on Assets-17.20%
Shares Outstanding194.52M
Shares Float164.38M
Beta0.18
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 9 analystsTarget 17.11
  • Strong Buy
    5
  • Buy
    3
  • Hold
    1

Ownership Breakdown

Institutions
77.85%
Insiders
0.42%
Retail / Other
21.73%

Top Institutional Holders

  • Deep Track Capital, LP
    19.25M9.90%
  • BlackRock Inc
    12.80M6.58%
  • TCG Crossover Management, LLC
    10.00M5.14%
  • State Street Corp
    7.15M3.67%
  • Vanguard Capital Management, LLC
    5.66M2.91%
  • Vanguard Portfolio Management, LLC
    5.38M2.77%
  • Marshall Wace Asset Management Ltd
    4.02M2.07%
  • Millennium Management LLC
    3.31M1.70%
  • Geode Capital Management, LLC
    3.11M1.60%
  • Trails Edge Capital Partners, LP
    2.66M1.37%
  • Alyeska Investment Group, L.P.
    2.64M1.36%
  • Two Sigma Investments LLC
    2.38M1.22%
  • Nuveen, LLC
    2.33M1.20%
  • Great Point Partners LLC
    1.74M0.90%

Top Fund Holders

  • State Street® SPDR® S&P® Biotech ETF
    8.54M4.39%
  • Vanguard MStar Total Stk Mkt Idx Invest
    5.75M2.96%
  • iShares Russell 2000 ETF
    5.08M2.61%
  • Vanguard Strategic Equity Inv
    2.67M1.37%
  • Fidelity Small Cap Index
    2.16M1.11%
  • iShares Russell 2000 Value ETF
    1.85M0.95%

Dividends

20172×
2.91Feb 6, 2017873.01Jan 20, 2017

Stock Splits

  • Sep 14, 20181:30